|Bid||0.05 x 100|
|Ask||199,999.95 x 100|
|Day's Range||10.90 - 11.35|
|52 Week Range||7.46 - 12.35|
|PE Ratio (TTM)||-87.70|
|Earnings Date||Nov 1, 2017 - Nov 6, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||12.75|
Research Desk Line-up: ICU Medical Post Earnings Coverage LONDON, UK / ACCESSWIRE / August 17, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for STAAR ...
MONROVIA, Calif., Aug. 15, 2017 /PRNewswire/ -- STAAR Surgical Company (STAA) a leading developer, manufacturer and marketer of implantable lenses and delivery systems for the eye, and Dr. Jong Ho Lee, Seoul/Busan BalGeunSeSang Eye Clinic today announced they have entered into an Strategic Cooperation Agreement to provide STAAR's EVO intraocular lenses (ICL) as a primary and premium option for patients seeking visual freedom from spectacles and contact lenses through refractive eye treatment. "I am very excited that my clinic became a strategic partnership account with STAAR Surgical Company and I expect to introduce the ICL to many more patients so they can experience the high quality of vision in their lives," said Dr. Jong Ho Lee, President of Seoul/Busan BalGeunSeSang Eye Clinic.
STAAR Surgical Company (STAA) moved big last session, as its shares jumped over 8% on the day.